GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Prestige Consumer Healthcare Inc (NYSE:PBH) » Definitions » Mohanram G-Score

Prestige Consumer Healthcare (Prestige Consumer Healthcare) Mohanram G-Score : 5 (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Prestige Consumer Healthcare Mohanram G-Score?

Mohanram G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. Companies have higher G-score tends to generate higher return. According to his study, the best growth stocks that have a G-Score greater than 6 tend to beat the market, while those with a G-Score lower than 1 tend to have negative absolute returns.

Thus, the zones of discrimination were as such:

Good or high score = 6, 7, 8
Bad or low score = 0, 1

Prestige Consumer Healthcare has an G-score of 5.

The historical rank and industry rank for Prestige Consumer Healthcare's Mohanram G-Score or its related term are showing as below:

PBH' s Mohanram G-Score Range Over the Past 10 Years
Min: 4   Med: 5   Max: 5
Current: 5

During the past 13 years, the highest Piotroski G-score of Prestige Consumer Healthcare was 5. The lowest was 4. And the median was 5.


Prestige Consumer Healthcare Mohanram G-Score Historical Data

The historical data trend for Prestige Consumer Healthcare's Mohanram G-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prestige Consumer Healthcare Mohanram G-Score Chart

Prestige Consumer Healthcare Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Mohanram G-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 5.00 5.00 5.00 5.00

Prestige Consumer Healthcare Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Mohanram G-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 4.00 5.00 5.00

Competitive Comparison of Prestige Consumer Healthcare's Mohanram G-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's Mohanram G-Score, along with its competitors' market caps and Mohanram G-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prestige Consumer Healthcare's Mohanram G-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's Mohanram G-Score distribution charts can be found below:

* The bar in red indicates where Prestige Consumer Healthcare's Mohanram G-Score falls into.



Prestige Consumer Healthcare Mohanram G-Score Calculation

The calculation of the Mohanram G-score consists of eight criteria. Assign one point for each criterion met, then add up all the points to get the G-Score.

Profitability

Question 1. Return on Assets (ROA)

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. It measures how well a company uses its asset to generate earnings.

Score 1 if ROA > ROA Industry Median, 0 otherwise.

Question 2. Cash ROA

Cash ROA equals to Cash Flow from Operations divided by average Total Assets. It measures how well a company uses its asset to generate cash.

Score 1 if Cash ROA > Cash ROA Industry Median, 0 otherwise.

Question 3. CFO and Net Income

Score 1 if CFO > Net Income, 0 otherwise.

Earnings Predictability

Question 4. Earnings Variability

Earnings Variability is measured as the variance of a firm's ROA in the past five years.

Score 1 if Earnings Variability < Earnings Variability Industry Median, 0 otherwise.

Question 5. Sales Growth Variability

Sales Growth Variability is measured as the 5-year variance in sales growth.

Score 1 if Sales Growth Variability < Sales Growth Variability Industry Median, 0 otherwise.

Accounting Conservatism

Question 6. Research & Development Intensity

Research & Development Intensity is calcualted by Research & Development divided by the beginning Total Assets.

Score 1 if Research & Development Intensity > Research & Development Intensity Industry Median, 0 otherwise.

Question 7. CAPEX Intensity

CAPEX Intensity is calcualted by Capital Expenditure divided by the beginning Total Assets.

Score 1 if CAPEX Intensity > CAPEX Intensity Industry Median, 0 otherwise.

Question 8. Advertising Expenditure Intensity

Advertising Expenditure Intensity is calcualted by Advertising Expenditure divided by the beginning Total Assets. Note that Advertising Expenditure is not reported as a seperate line item for many companies, thus Selling, General, & Admin. Expense is used in this calculation.

Score 1 if Advertising Expenditure Intensity > Advertising Expenditure Intensity Industry Median, 0 otherwise.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note that all the Industry Median used for comparison in his original research, are substituted with Sector Median due to the limitation of data within certain countries.

Good or high score = 6, 7, 8
Bad or low score = 0, 1

Prestige Consumer Healthcare has an G-score of 5.

Prestige Consumer Healthcare  (NYSE:PBH) Mohanram G-Score Explanation

Partha Mohanram is the John H. Watson Chair in Value Investing at Rotman and the Acting Vice-Dean of Research Strategy and Resources.

In 2000, he wrote a research paper called "Separating Winners from Losers Among Low Book-to-Market Stocks Using Financial Statement Analysis".

This paper tests whether a strategy based on financial statement analysis of low book-to-market (growth) stocks is successful in differentiating between winners and losers in terms of future stock performance. Based on the research, a strategy based on buying high G-score (6, 7 or 8) firms and shorting low G-score (0 or 1) firms consistently earns significant excess returns. Further, the results do not support a risk based explanation for the book-to-market effect as the strategy returns positive returns in all years, and firms that ex-ante appear less risky have better future returns.

To conclude, one can use a modified fundamental analysis strategy (G-score) to identify mispricing and earn substantial abnormal returns.


Prestige Consumer Healthcare Mohanram G-Score Related Terms

Thank you for viewing the detailed overview of Prestige Consumer Healthcare's Mohanram G-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Prestige Consumer Healthcare (Prestige Consumer Healthcare) Business Description

Traded in Other Exchanges
Address
660 White Plains Road, Tarrytown, NY, USA, 10591
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Executives
Mary Beth Fritz officer: Senior VP Quality & Regulatory 660 WHITE PLAINS RD, 2ND FL, TARRYTOWN NY 10591
Ronald M. Lombardi officer: Chief Executive Officer 660 WHITE PLAINS RD., TARRYTOWN NY 10591
James Darecca director C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Christine Sacco officer: Chief Financial Officer C/O SMART BALANCE, INC., 115 WEST CENTURY ROAD, SUITE 260, PARAMUS NJ 07652
Adel Mekhail other: EVP, Marketing & Sales 660 WHITE PLAINS RD., 2ND FL, TARRYTOWN NY 10591
William P'pool officer: See Remarks 2400 WEST LLOYD EXPRESSWAY, EVANSVILLE IL 47721
Celeste A. Clark director C/O ADVANCEPIERRE FOODS HOLDINGS, INC., 9987 CARVER ROAD, BLUE ASH OH 45242
Christopher J Coughlin director
Natale S Ricciardi director C/O MORRIS COMMUNICATIONS CORP, 725 BROAD ST., AUGUSTA GA 30903
James M Jenness director PO BOX 3599, BATTLECREEK MI 49016-3599
John E Byom director 660 WHITE PLAINS RD., TARRYTOWN NY 10591
Sheila Hopkins director C/O WARNACO INC, 90 PARK AVENUE, NEW YORK NY 10016
Dawn M. Zier director 600 OFFICE CENTER DRIVE, FORT WASHINGTON PA 19034
Jeffrey Zerillo officer: Senior VP Operations 660 WHITE PLAINS RD, 2ND FL, TARRYTOWN NY 10591
Timothy Connors officer: Chief Marketing Officer 660 WHITE PLAINS RD., SUITE 205, TARRYTOWN NY 10591